Board Of Directors
Our distinguished members of the Board of Directors champion and support the Music Beats Cancer mission.
Mona S. Jhaveri, Ph.D.
Dr. Jhaveri is the Founder and Executive Director of Music Beats Cancer. Dr. Jhaveri holds a Doctorate in Biochemistry from the Bowman Gray School of Medicine of Wake Forest University. She trained as a post-doctoral fellow at the National Cancer Institute and at the Lombardi Cancer Center of Georgetown, where she was granted the SPORE Fellowship Award for Breast Cancer Research. Dr. Jhaveri specialized in intellectual property and technology transfer management while at the Ludwig Institute for Cancer Research.
In 2005, Dr. Jhaveri founded Foligo Therapeutics, Inc. to develop and commercialize a DNA-based therapeutic compound as a potential treatment for ovarian cancer. In 2010, Foligo’s poor funding position resulted in the shutdown of its R&D operation and abandonment of its lead compound in development. Dr. Jhaveri was inspired to launch Music Beats Cancer to help address the critical funding bottleneck that constrains cancer product development.
Chris Lee has worked in more than thirty countries across six continents, developing strategies and investing in solutions to hunger, health, climate change, and a range of other critical challenges. His writing on social, scientific, and financial innovation has appeared in popular outlets such as Reuters and The Hill, as well as professional publications including BioCentury, MIT Innovations, and American Banker. His first novel, Between the Shimmer & the Blinding—a multi-generational family drama exploring the ethics of genetic engineering—was published by New Degree Press in 2022. Over his career, Lee has served on various government, non-profit, and company advisory boards with a common purpose of attracting more resources to underserved markets. A multi-instrumentalist and University of Virginia graduate, he lives with his wife and children in Washington, DC.
Reginald Swift, Ph.D is the Founder and CEO of Rubix LS, a visionary leader in healthcare innovation. With a background in mechanical engineering, he is renowned for pioneering the use of regenerative metals to target diseases like Multiple Sclerosis, ALS, PLS, PKAN, and rare infectious diseases. In addition to groundbreaking research, Reginald Swift is deeply committed to patient-centered care and actively promotes culturally competent clinical trials, ensuring that underserved patient communities have equitable access to cutting-edge treatments. His work is transforming the healthcare landscape, offering hope to individuals facing complex medical challenges, and making Rubix LS a leader in healthcare innovation and healthcare equity advocacy.